-
公开(公告)号:US06270984B1
公开(公告)日:2001-08-07
申请号:US09540245
申请日:2000-03-31
IPC分类号: G01N3383
CPC分类号: C07K14/70503 , A61K38/00 , C07K14/4702 , G01N33/566 , G01N33/68 , G01N2333/43573 , G01N2500/02
摘要: Disclosed are methods and compositions for identifying agents which modulate the interaction of Robo and a Robo ligand and for modulating the interaction of Robo and a Robo ligand. The methods for identifying Robo:ligand modulators find particular application in commercial drug screens. These methods generally comprise (1) combining a Robo polypeptide, a Slit polypeptide and a candidate agent under conditions whereby, but for the presence of the agent, the Robo and Slit polypeptides engage in a first interaction, and (2) determining a second interaction of the Robo and Slit polypeptides in the presence of the agent, wherein a difference between the first and second interactions indicates that the agent modulates the interaction of the Robo and Slit polypeptides. The subject methods of modulating the interaction of Robo and a Robo ligand involve combining a Robo polypeptide, a Slit polypeptide and a modulator under conditions whereby, but for the presence of the modulator, the Robo and Slit polypeptides engage in a first interaction, whereby the Robo and Slit polypeptides engage in a second interaction different from the first interaction. In a particular embodiment, the modulator is dominant negative form of the Robo or Slit polypeptide.
摘要翻译: 公开了用于鉴定调节Robo和Robo配体的相互作用并调节Robo和Robo配体的相互作用的试剂的方法和组合物。 用于鉴定Robo:配体调节剂的方法在商业药物筛选中发现具体应用。 这些方法通常包括(1)在条件下组合Robo多肽,狭缝多肽和候选试剂,但是对于所述试剂的存在,所述Robo和狭缝多肽参与第一相互作用,和(2)确定第二相互作用 的Robo和Slit多肽,其中所述第一和第二相互作用之间的差异指示所述试剂调节所述Robo和Slit多肽的相互作用。 调节Robo和Robo配体的相互作用的主题方法包括在条件下组合Robo多肽,狭缝多肽和调节剂,但是对于调节剂的存在,Robo和Slit多肽参与第一相互作用,由此 Robo和Slit多肽参与与第一相互作用不同的第二相互作用。 在一个具体实施方案中,调节剂是Robo或Slit多肽的显性阴性形式。
-
公开(公告)号:US6046015A
公开(公告)日:2000-04-04
申请号:US191647
申请日:1998-11-13
IPC分类号: C12N15/09 , A61K38/00 , A61K38/17 , A61P43/00 , C07K14/47 , C07K14/705 , C07K16/18 , C12N15/12 , G01N33/15 , G01N33/50 , G01N33/566 , G01N33/68 , G01N33/53 , C07K7/08 , C12N5/02
CPC分类号: C07K14/70503 , C07K14/4702 , G01N33/566 , G01N33/68 , A61K38/00 , G01N2333/43573 , G01N2500/02
摘要: Disclosed are methods and compositions for identifing agents which modulate the interaction of Robo and a Robo ligand and for modulating the interaction of Robo and a Robo ligand. The methods for identifying Robo:ligand modulators find particular application in commercial drug screens. These methods generally comprise (1) combining a Robo polypeptide, a Slit polypeptide and a candidate agent under conditions whereby, but for the presence of the agent, the Robo and Slit polypeptides engage in a first interaction, and (2) determining a second interaction of the Robo and Slit polypeptides in the presence of the agent, wherein a difference between the first and second interactions indicates that the agent modulates the interaction of the Robo and Slit polypeptides. The subject methods of modulating the interaction of Robo and a Robo ligand involve combining a Robo polypeptide, a Slit polypeptide and a modulator under conditions whereby, but for the presence of the modulator, the Robo and Slit polypeptides engage in a first interaction, whereby the Robo and Slit polypeptides engage in a second interaction different from the first interaction. In a particular embodiment, the modulator is dominant negative form of the Robo or Slit polypeptide.
摘要翻译: 公开了用于调节Robo和Robo配体的相互作用并用于调节Robo和Robo配体的相互作用的识别剂的方法和组合物。 用于鉴定Robo:配体调节剂的方法在商业药物筛选中发现具体应用。 这些方法通常包括(1)在条件下组合Robo多肽,狭缝多肽和候选试剂,但是对于所述试剂的存在,所述Robo和狭缝多肽参与第一相互作用,和(2)确定第二相互作用 的Robo和Slit多肽,其中所述第一和第二相互作用之间的差异指示所述试剂调节所述Robo和Slit多肽的相互作用。 调节Robo和Robo配体的相互作用的主题方法包括在条件下组合Robo多肽,狭缝多肽和调节剂,但是对于调节剂的存在,Robo和Slit多肽参与第一相互作用,由此 Robo和Slit多肽参与与第一相互作用不同的第二相互作用。 在一个具体实施方案中,调节剂是Robo或Slit多肽的显性阴性形式。
-
公开(公告)号:US20090155928A1
公开(公告)日:2009-06-18
申请号:US11891963
申请日:2007-08-13
IPC分类号: G01N33/566 , C07K14/00 , C12N15/11
CPC分类号: C07K14/70503 , A61K38/00 , C07K14/4702 , G01N33/566 , G01N33/68 , G01N2333/43573 , G01N2500/02
摘要: Disclosed are methods and compositions for identifying agents which modulate the interaction of Robo and a Robo ligand and for modulating the interaction of Robo and a Robo ligand. The methods for identifying Robo:ligand modulators find particular application in commercial drug screens. These methods generally comprise (1) combining a Robo polypeptide, a Slit polypeptide and a candidate agent under conditions whereby, but for the presence of the agent, the Robo and Slit polypeptides engage in a first interaction, and (2) determining a second interaction of the Robo and Slit polypeptides in the presence of the agent, wherein a difference between the first and second interactions indicates that the aget modulates the interaction of the Robo and Slit polypeptides. The subject methods of modulating the interaction of Robo and a Robo ligand involve combining a Robo polypeptide, a Slit polypeptide and a modulator under conditions whereby, but for the presence of the modulator, the Robo and Slit polypeptides engage in a first interaction, whereby the Robo and Slit polypeptides engage in a second interaction different from the first interaction. In a particular embodiment, the modulator is dominant negative form of the Robo or Slit polypeptide.
摘要翻译: 公开了用于鉴定调节Robo和Robo配体的相互作用并调节Robo和Robo配体的相互作用的试剂的方法和组合物。 用于鉴定Robo:配体调节剂的方法在商业药物筛选中发现具体应用。 这些方法通常包括(1)在条件下组合Robo多肽,狭缝多肽和候选试剂,但是对于所述试剂的存在,所述Robo和狭缝多肽参与第一相互作用,和(2)确定第二相互作用 的Robo和Slit多肽,其中所述第一和第二相互作用之间的差异指示所述琼脂调节所述Robo和Slit多肽的相互作用。 调节Robo和Robo配体的相互作用的主题方法包括在条件下组合Robo多肽,狭缝多肽和调节剂,但是对于调节剂的存在,Robo和Slit多肽参与第一相互作用,由此 Robo和Slit多肽参与与第一相互作用不同的第二相互作用。 在一个具体实施方案中,调节剂是Robo或Slit多肽的显性阴性形式。
-
公开(公告)号:US06861228B2
公开(公告)日:2005-03-01
申请号:US10289776
申请日:2002-11-06
IPC分类号: C12N15/09 , A61K38/00 , A61K38/17 , A61P43/00 , C07K14/47 , C07K14/705 , C07K16/18 , C12N15/12 , G01N33/15 , G01N33/50 , G01N33/566 , G01N33/68 , G01N33/53 , A61K39/395
CPC分类号: C07K14/70503 , A61K38/00 , C07K14/4702 , G01N33/566 , G01N33/68 , G01N2333/43573 , G01N2500/02
摘要: Disclosed are methods and compositions for identifying agents which modulate the interaction of Robo and a Robo ligand and for modulating the interaction of Robo and a Robo ligand. The methods for identifying Robo:ligand modulators find particular application in commercial drug screens. These methods generally comprise (1) combining a Robo polypeptide, a Slit polypeptide and a candidate agent under conditions whereby, but for the presence of the agent, the Robo and Slit polypeptides engage in a first interaction, and (2) determining a second interaction of the Robo and Slit polypeptides in the presence of the agent, wherein a difference between the first and second interactions indicates that the aget modulates the interaction of the Robo and Slit polypeptides. The subject methods of modulating the interaction of Robo and a Robo ligand involve combining a Robo polypeptide, a Slit polypeptide and a modulator under conditions whereby, but for the presence of the modulator, the Robo and Slit polypeptides engage in a first interaction, whereby the Robo and Slit polypeptides engage in a second interaction different from the first interaction. In a particular embodiment, the modulator is dominant negative form of the Robo or Slit polypeptide.
摘要翻译: 公开了用于鉴定调节Robo和Robo配体的相互作用并调节Robo和Robo配体的相互作用的试剂的方法和组合物。 用于鉴定Robo:配体调节剂的方法在商业药物筛选中发现具体应用。 这些方法通常包括(1)在条件下组合Robo多肽,狭缝多肽和候选试剂,但是对于所述试剂的存在,所述Robo和狭缝多肽参与第一相互作用,和(2)确定第二相互作用 的Robo和Slit多肽,其中所述第一和第二相互作用之间的差异指示所述琼脂调节所述Robo和Slit多肽的相互作用。 调节Robo和Robo配体的相互作用的主题方法包括在条件下组合Robo多肽,狭缝多肽和调节剂,但是对于调节剂的存在,Robo和Slit多肽参与第一相互作用,由此 Robo和Slit多肽参与与第一相互作用不同的第二相互作用。 在一个具体实施方案中,调节剂是Robo或Slit多肽的显性阴性形式。
-
公开(公告)号:US06270995B1
公开(公告)日:2001-08-07
申请号:US09540153
申请日:2000-03-31
IPC分类号: C12P2102
CPC分类号: C07K14/70503 , A61K38/00 , C07K14/4702 , G01N33/566 , G01N33/68 , G01N2333/43573 , G01N2500/02
摘要: Disclosed are methods and compositions for identifying agents which modulate the interaction of Robo and a Robo ligand and for modulating the interaction of Robo and a Robo ligand. The methods for identifying Robo:ligand modulators find particular application in commercial drug screens. These methods generally comprise (1) combining a Robo polypeptide, a Slit polypeptide and a candidate agent under conditions whereby, but for the presence of the agent, the Robo and Slit polypeptides engage in a first interaction, and (2) determining a second interaction of the Robo and Slit polypeptides in the presence of the agent, wherein a difference between the first and second interactions indicates that the aget modulates the interaction of the Robo and Slit polypeptides. The subject methods of modulating the interaction of Robo and a Robo ligand involve combining a Robo polypeptide, a Slit polypeptide and a modulator under conditions whereby, but for the presence of the modulator, the Robo and Slit polypeptides engage in a first interaction, whereby the Robo and Slit polypeptides engage in a second interaction different from the first interaction. In a particular embodiment, the modulator is dominant negative form of the Robo or Slit polypeptide.
摘要翻译: 公开了用于鉴定调节Robo和Robo配体的相互作用并调节Robo和Robo配体的相互作用的试剂的方法和组合物。 用于鉴定Robo:配体调节剂的方法在商业药物筛选中发现具体应用。 这些方法通常包括(1)在条件下组合Robo多肽,狭缝多肽和候选试剂,但是对于所述试剂的存在,所述Robo和狭缝多肽参与第一相互作用,和(2)确定第二相互作用 的Robo和Slit多肽,其中所述第一和第二相互作用之间的差异指示所述琼脂调节所述Robo和Slit多肽的相互作用。 调节Robo和Robo配体的相互作用的主题方法包括在条件下组合Robo多肽,狭缝多肽和调节剂,但是对于调节剂的存在,Robo和Slit多肽参与第一相互作用,由此 Robo和Slit多肽参与与第一相互作用不同的第二相互作用。 在一个具体实施方案中,调节剂是Robo或Slit多肽的显性阴性形式。
-
公开(公告)号:US20050196783A1
公开(公告)日:2005-09-08
申请号:US11022546
申请日:2004-12-23
申请人: Corey Goodman , Thomas Kidd , Katja Brose , Marc Tessier-Lavigne
发明人: Corey Goodman , Thomas Kidd , Katja Brose , Marc Tessier-Lavigne
IPC分类号: C12N15/09 , A61K38/00 , A61K38/17 , A61P43/00 , C07K14/47 , C07K14/705 , C07K16/18 , C12N15/12 , G01N33/15 , G01N33/50 , G01N33/566 , G01N33/68 , C12Q1/68 , A61K39/395 , C07H21/04 , C07K16/28 , G01N33/53 , G01N33/567
CPC分类号: C07K14/70503 , A61K38/00 , C07K14/4702 , G01N33/566 , G01N33/68 , G01N2333/43573 , G01N2500/02
摘要: Disclosed are methods and compositions for identifying agents which modulate the interaction of Robo and a Robo ligand and for modulating the interaction of Robo and a Robo ligand. The methods for identifying Robo:ligand modulators find particular application in commercial drug screens. These methods generally comprise (1) combining a Robo polypeptide, a Slit polypeptide and a candidate agent under conditions whereby, but for the presence of the agent, the Robo and Slit polypeptides engage in a first interaction, and (2) determining a second interaction of the Robo and Slit polypeptides in the presence of the agent, wherein a difference between the first and second interactions indicates that the aget modulates the interaction of the Robo and Slit polypeptides. The subject methods of modulating the interaction of Robo and a Robo ligand involve combining a Robo polypeptide, a Slit polypeptide and a modulator under conditions whereby, but for the presence of the modulator, the Robo and Slit polypeptides engage in a first interaction, whereby the Robo and Slit polypeptides engage in a second interaction different from the first interaction. In a particular embodiment, the modulator is dominant negative form of the Robo or Slit polypeptide.
-
公开(公告)号:US07005411B1
公开(公告)日:2006-02-28
申请号:US09191651
申请日:1998-11-13
申请人: Corey S. Goodman , Thomas Kidd , Guy Tear , Claire Russell , Kevin J. Mitchell
发明人: Corey S. Goodman , Thomas Kidd , Guy Tear , Claire Russell , Kevin J. Mitchell
CPC分类号: A61K38/1709
摘要: The amount of active Robo expressed on a cell is modified by modulating the effective amount of a Comm polypeptide in contact with the cell, whereby the amount of expressed active Robo is modulated inversely with the modulation of the effective amount of the Comm polypeptide in contact with the cell. In a particular embodiment, the Comm polypeptide is provided to the cell by exogenously in a pharmaceutically acceptable composition. In another aspect, the invention provides methods of screening for agents which modulate Robo-Comm interactions. These methods generally involve forming a mixture of a Robo-expressing cell, a Comm polypeptide and a candidate agent, and determining the effect of the agent on the amount of Robo expressed by the cell.
摘要翻译: 通过调节与细胞接触的Comm多肽的有效量来修饰在细胞上表达的活性Robo的量,由此与表达的活性Robo的有效量的调节相反地调节与Comm接触的Comm多肽的有效量 细胞。 在一个具体实施方案中,通过外源地在药学上可接受的组合物中将Comm多肽提供给细胞。 另一方面,本发明提供筛选调节Robo-Comm相互作用的试剂的方法。 这些方法通常涉及形成Robo表达细胞,Comm多肽和候选试剂的混合物,并确定试剂对细胞表达的Robo量的影响。
-
公开(公告)号:US08426147B2
公开(公告)日:2013-04-23
申请号:US12325914
申请日:2008-12-01
IPC分类号: G01N33/53
CPC分类号: G01N33/57484 , A01K2267/0331 , C07K14/4702 , C12Q1/6886 , C12Q2600/136 , G01N33/566 , G01N33/57407 , G01N2333/4704 , G01N2333/70567 , G01N2333/9121 , G01N2500/10
摘要: Human ROR genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of ROR are provided.
摘要翻译: 人类ROR基因被鉴定为p21途径的调节剂,因此是与缺陷型p21功能相关的疾病的治疗靶点。 提供了用于鉴定p21调节剂的方法,包括筛选调节ROR活性的药剂。
-
公开(公告)号:US20090149413A1
公开(公告)日:2009-06-11
申请号:US12325914
申请日:2008-12-01
IPC分类号: A61K31/7105 , C12Q1/68
CPC分类号: G01N33/57484 , A01K2267/0331 , C07K14/4702 , C12Q1/6886 , C12Q2600/136 , G01N33/566 , G01N33/57407 , G01N2333/4704 , G01N2333/70567 , G01N2333/9121 , G01N2500/10
摘要: Human ROR genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of ROR are provided.
摘要翻译: 人类ROR基因被鉴定为p21途径的调节剂,因此是与缺陷型p21功能相关的疾病的治疗靶点。 提供了用于鉴定p21调节剂的方法,包括筛选调节ROR活性的药剂。
-
公开(公告)号:US20060101530A1
公开(公告)日:2006-05-11
申请号:US10528032
申请日:2003-09-15
IPC分类号: A01K67/027 , C12Q1/68 , G01N33/574
CPC分类号: G01N33/57484 , A01K2267/0331 , C07K14/4702 , C12Q1/6886 , C12Q2600/136 , G01N33/566 , G01N33/57407 , G01N2333/4704 , G01N2333/70567 , G01N2333/9121 , G01N2500/10
摘要: Human ROR genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of ROR are provided.
摘要翻译: 人类ROR基因被鉴定为p21途径的调节剂,因此是与缺陷型p21功能相关的疾病的治疗靶点。 提供了用于鉴定p21调节剂的方法,包括筛选调节ROR活性的药剂。
-
-
-
-
-
-
-
-
-